Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124923842 | 12492384 | 2 | F | 201605 | 20160706 | 20160623 | 20160712 | EXP | FR-PFIZER INC-2016304566 | PFIZER | 66.00 | YR | F | Y | 0.00000 | 20160712 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124923842 | 12492384 | 1 | PS | ALPRAZOLAM. | ALPRAZOLAM | 1 | Oral | 0.5 MG, 3X/DAY | Y | 18276 | .5 | MG | TID | ||||||
| 124923842 | 12492384 | 2 | SS | LYRICA | PREGABALIN | 1 | Oral | 25 MG, 1X/DAY IN THE EVENING | 21446 | 25 | MG | CAPSULE, HARD | QD | ||||||
| 124923842 | 12492384 | 3 | SS | SERTRALINE | SERTRALINE HYDROCHLORIDE | 1 | Oral | 50 MG, 2X/DAY | Y | 19839 | 50 | MG | BID | ||||||
| 124923842 | 12492384 | 4 | SS | XEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 50 MG, DAILY TO BE PROGRESSIVELY INCREASED | Y | 0 | 50 | MG | PROLONGED-RELEASE TABLET | ||||||
| 124923842 | 12492384 | 5 | SS | XEROQUEL | QUETIAPINE FUMARATE | 1 | Oral | 8 DF OF 50 MG, SINGLE IN THE EVENING | Y | 0 | 400 | MG | PROLONGED-RELEASE TABLET | ||||||
| 124923842 | 12492384 | 6 | SS | KEPPRA | LEVETIRACETAM | 1 | Oral | 500 MG, 2X/DAY | 0 | 500 | MG | FILM-COATED TABLET | BID | ||||||
| 124923842 | 12492384 | 7 | SS | NORDAZEPAM | NORDAZEPAM | 1 | UNK | U | 0 | ||||||||||
| 124923842 | 12492384 | 8 | SS | ACUPAN | NEFOPAM HYDROCHLORIDE | 1 | Oral | 20 MG, 3X/DAY | U | 0 | 20 | MG | TABLET | TID | |||||
| 124923842 | 12492384 | 9 | SS | CODEINE | CODEINE | 1 | UNK | Y | 0 | ||||||||||
| 124923842 | 12492384 | 10 | C | LIDOCAINE. | LIDOCAINE | 1 | UNK | 0 | |||||||||||
| 124923842 | 12492384 | 11 | C | DAFALGAN | ACETAMINOPHEN | 1 | 3X/DAY 1 DF IN THE MORNING, 1 AT NOON AND 2 IN THE EVENING | 0 | CAPSULE | TID | |||||||||
| 124923842 | 12492384 | 12 | C | DIFFU K | POTASSIUM CHLORIDE | 1 | Oral | 2 DF, 3X/DAY | 0 | 2 | DF | CAPSULE | TID | ||||||
| 124923842 | 12492384 | 13 | C | SPASFON | PHLOROGLUCINOL | 1 | 2 DF, 3X/DAY | 0 | 2 | DF | TID | ||||||||
| 124923842 | 12492384 | 14 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Subcutaneous | 0.6 MG, 1X/DAY | 0 | .6 | MG | QD | |||||||
| 124923842 | 12492384 | 15 | C | BETNEVAL | BETAMETHASONE VALERATE | 1 | Cutaneous | 1 APPLICATION, 2X/DAY | 0 | 1 | DF | BID | |||||||
| 124923842 | 12492384 | 16 | C | CERULYSE | 2 | INTRA-AURAL | 1X/DAY | 0 | QD | ||||||||||
| 124923842 | 12492384 | 17 | C | FUNGIZONE | AMPHOTERICIN B | 1 | Oral | IN THE MORNING AND IN THE EVENING | 0 | BID | |||||||||
| 124923842 | 12492384 | 18 | C | FRESUBIN | AMINO ACIDSDEXTROSEELECTROLYTES NOSSOYBEAN OILVITAMINS | 1 | 500 ML, DAILY | 0 | 500 | ML |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124923842 | 12492384 | 4 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124923842 | 12492384 | OT |
| 124923842 | 12492384 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124923842 | 12492384 | Coma | |
| 124923842 | 12492384 | Miosis | |
| 124923842 | 12492384 | Pain | |
| 124923842 | 12492384 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124923842 | 12492384 | 5 | 20160524 | 0 |